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ABSTRACT
Coronaviruses have caused at least three large scale epidemics/pandemics in humans
over the past twenty years – severe acute respiratory syndrome (SARS) in 2003; the
Middle East respiratory syndrome (MERS) in 2012; novel coronavirus disease (COVID-19)
in 2019 – taking many lives all over the world. World Health Organization (WHO) named
the new virus responsible for COVID-19 as SARS-CoV-2.
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INTRODUCTION
Coronaviruses have caused at least three large scale
epidemics/pandemics in humans over the past
twenty years – severe acute respiratory syndrome
(SARS) in 2003; the Middle East respiratory syndrome
(MERS) in 2012; novel coronavirus disease (COVID-19)
in 2019 – taking many lives all over the world. World
Health Organization (WHO) named the new virus
responsible for COVID-19 as SARS-CoV-2.
For the SARS outbreak, the case-fatality rate was
11% while for MERS it was 34%. 1 According to Johns
Hopkins University Coronavirus Resource Center, the
case-fatality rate for COVID-19 pandemic varies in
reports from different countries. The mortality rate
in the top ten most affected countries worldwide is
between 4.5-16.3%. This virus is highly contagious
and is responsible for taking more than 320,000
lives and affecting around 5 million people around
the world, as of mid-May 2020. The mortality is
almost twice higher in males compared to females.2
The White House Coronavirus Task Force estimated
there will be between 100,000-240,000 deaths
due to COVID-19 in the US alone. Despite the
implementation of many preventive policies all
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over the world i.e. social distancing, wearing masks
etc., this virus is continuing to kill people, has taxed
community health care centers, and therapeutic
options are currently limited.3
There is an urgent need to better understand
the pathophysiologic mechanism of the virus life
cycle and further, find a way to prevent its fatal
complications.
VIRUS CYCLE
This virus has a strong affinity toward angiotensinconverting enzyme 2 (ACE2) receptors in the
respiratory system via S Protein on its envelope. S
Protein is composed of one amino-terminal (S1) and
one carboxy-terminal (S2). Cleavage at S1-S2 junction
by protease is essential to activate membrane fusion.
After binding, there are two different pathways
through which the virus can enter the cell. First is the
endosomal pathway which allows the virus entry at
the plasma membrane. In the endosomal pathway,
cathepsin [Cysteine protease] is responsible for the
activation of membrane fusion and endocytosis.
Low pH facilitates the endosomal cell entry in
this path. Second is the non-endosomal pathway
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Figure 1: COVID-19 cell entry via the Non-Endosomal pathway.

which allows the virus entry into the cell without
endocytosis. In this pathway, TMPRSS2 [Serine
protease] is needed to prime the spikes and allow
the virus entry at the plasma membrane. After the
virus enters the cell, in the next phase, the virus’s RNA
replicates and eventually causes cell death. After cell
death, the virus continues this cycle and infects other
cells.4,5 (Figure 1)
A host serine protease (TMPRSS2) is responsible for
priming the spikes and allows the virus entry at the
plasma membrane via the non-endosomal pathway.
Cleavage at S1-S2 junction by TMPRSS2 activates
membrane fusion. Bromhexine hydrochloride is
shown to act as a bioavailable inhibitor of TMPRSS2.
THERAPEUTIC OPTIONS
Endocytosis inhibitors
Many medications have been used to interfere and
block the virus cycle with different results. It has
been proposed that chloroquine, by increasing the
endosomal pH, may abrogate virus-endosomal fusion
and endocytosis, in addition to possibly exerting an
antiviral effect inside the endosome. There is limited
promising data about the efficacy of chloroquine or
hydroxychloroquine in COVID-19. Amiodarone might
be another effective agent in blocking endocytosis,
but no solid data is yet available to show its efficacy.6
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TMPRSS2 inhibitors
Blocking the non-endosomal pathway might be
an effective option to control COVID infection. The
serine protease (TMPRSS2) could be a good target
to prevent viral infection by blocking the fusion
and priming the processes of the virus.5 There are
some medications such as camostat mesylate or
nafamostat, which are used in chronic pancreatitis
to inhibit the TMPRSS2 and eventually cell entry of
SARS-COV-2. A trial using nafamostat is ongoing. No
data is available now.6
TMPRSS2 is a member of the type II transmembrane
serine protease (TTSP) family. TTMPRS2 is expressed
in the GI system, lungs, kidneys, and prostate. It has
been shown that the presence of serine protease
of TMPRSS2 is very essential for the influenza
virus infection. This enzyme cleaves the surface
glycoprotein hemagglutinin (HA) of the influenza
virus and ensues virus fusion and propagation. 7 The
inhibition of TMPRSS2 by bromhexine can prevent
influenza infection.8 In addition to bromhexine,
other synthetic inhibitors of TMPRSS2 have been
developed and have demonstrated efficacy in
preventing influenza infection. However, these
inhibitors also have strong affinities for other
proteases, such as matriptase, making their precise
therapeutic mechanism unclear.9
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TMPRSS2 expression in the prostate is driven by
androgen receptor signaling. TMPRSS2 mRNA
expression is upregulated and remains elevated
in androgen-stimulated prostate cancer. The
administration of bromhexine hydrochloride, an
inhibitor of TMPRSS2, was able to suppress distant
metastasis to the liver and lungs sites in mice
models via modulating of ERG oncogene.10 This link
between androgen receptor signaling and TMPRSS2
expression could explain the higher prevalence and
severity of coronavirus in males as compared to
females.11
Others
Many antivirals, HIV medications, and steroids
have been tried with no promising results in
COVID-19, except limited clinical improvement in
compassionate use of remedisivir which led to an
emergency approval of medication by FDA but a
multicenter, randomized, double-blind, placebocontrolled study did not show any significant clinical
benefit.12,13
There is a debate about the role of angiotensinconverting enzyme (ACE) inhibitors and angiotensinreceptor blockers (ARB) in COVID-19. The data
showed that increasing the number of ACE2
receptors may not translate, as a rule, to getting
the COVID-19 infection. It seems ACE2 receptor in
conjunction with TMPRSS2, is a recipe for getting the
infection.6
RECOMMENDATION
Many different medications have been tried to
prevent, control or treat COVID-19 with debatable
results. Bromhexine hydrochloride is an inexpensive
and safe over-the-counter medication that has been
used as a mucolytic since 1963 in clinical medicine.
It increases the secretion of various mucous
components and improves mucociliary clearance.14
This medication can also inhibit TMPRSS2 and
potentially prevent priming of the S-protein of
coronavirus and abort the process of the virus entry
into the cell.15
This idea has major public health importance and
could change clinical practice or provide a novel
approach to COVID-19 infection for clinicians,
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especially in underserved and rural areas with limited
access to tertiary medical centers. The authors
propose to use bromhexine 8 mg two or three
times a day as a prophylactic/therapeutic measure
during the COVID-19 pandemic. This monotherapy
is safe and very inexpensive and therefore, most
everybody can afford to get it. Further studies and
clinical trials are needed to prove the validity of this
medication therapy in COVID-19 infection. Multiple
trials for bromhexine alone or in combination with
hydroxychloroquine have been submitted but no
results have yet been available.
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